ID   CUTO-28
AC   CVCL_C8T2
SY   CUTO28; Colorado University Thoracic Oncology 28
DR   GEO; GSM7675367
DR   GEO; GSM7675368
DR   GEO; GSM7675369
DR   GEO; GSM7675370
DR   GEO; GSM7675371
DR   GEO; GSM7675372
DR   Wikidata; Q123030991
RX   DOI=10.1158/1535-7163.TARG-21-P076;
RX   DOI=10.1158/1538-7445.AM2020-3003;
RX   DOI=10.63028/10067/2105480151162165141;
RX   PubMed=29636358;
RX   PubMed=36101520;
WW   Provider; UCSM; -; https://web.archive.org/web/20241201182000/https://cuamc.technologypublisher.com/technology/48353
CC   Sequence variation: Gene fusion; HGNC; HGNC:10261; ROS1 + HGNC; HGNC:12012; TPM3; Name(s)=TPM3-ROS1 (DOI=10.1158/1538-7445.AM2020-3003; PubMed=36101520).
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 05-10-23; Last updated: 10-04-25; Version: 5
//
RX   DOI=10.1158/1535-7163.TARG-21-P076;
RA   Tyler L.C., Le A.T., Nijmeh H., Bao L.-M., Turner K.,
RA   Christianson J., Doebele R.C.;
RT   "Novel mechanisms of acquired TKI resistance in ROS1+ NSCLC.";
RL   Mol. Cancer Ther. 20 Suppl. 12:P076-P076(2021).
//
RX   DOI=10.1158/1538-7445.AM2020-3003;
RA   Tyler L.C., Le A.T., Nijmeh H., Doebele R.C.;
RT   "MET mediates entrectinib resistance in ROS1 gene fusion positive
RT   NSCLC.";
RL   Cancer Res. 80 Suppl. 16:3003-3003(2020).
//
RX   DOI=10.63028/10067/2105480151162165141;
RA   Terrones M.;
RT   "Profiling targeted therapy responses in ROS1+ non-small cell lung
RT   cancer using genomically engineered patient-derived cell lines.";
RL   Thesis PhD (2024); University of Antwerp; Antwerp; Belgium.
//
RX   PubMed=29636358; DOI=10.1158/1078-0432.CCR-17-2452; PMCID=PMC6050099;
RA   McCoach C.E., Le A.T., Gowan K., Jones K.L., Schubert L., Doak A.E.,
RA   Estrada-Bernal A., Davies K.D., Merrick D.T., Bunn P.A. Jr.,
RA   Purcell W.T., Dziadziuszko R., Varella-Garcia M., Aisner D.L.,
RA   Camidge D.R., Doebele R.C.;
RT   "Resistance mechanisms to targeted therapies in ROS1(+) and ALK(+)
RT   non-small cell lung cancer.";
RL   Clin. Cancer Res. 24:3334-3347(2018).
//
RX   PubMed=36101520; DOI=10.1111/1759-7714.14656; PMCID=PMC9626307;
RA   Tyler L.C., Le A.T., Chen N., Nijmeh H., Bao L.-M., Wilson T.R.,
RA   Chen D., Simmons B., Turner K.M., Perusse D., Kasibhatla S.,
RA   Christiansen J., Dudek A.Z., Doebele R.C.;
RT   "MET gene amplification is a mechanism of resistance to entrectinib in
RT   ROS1+ NSCLC.";
RL   Thorac. Cancer 13:3032-3041(2022).
//